Education
About Us
Working with TipRanks
Follow Us
aTyr Pharma (ATYR)
NASDAQ:ATYR
ATYR Stock Chart & Stats
$0.93
-$0.23(-5.91%)
At close: 4:00 PM EST
$0.93
-$0.23(-5.91%)
Day’s Range― - ―
52-Week Range$0.64 - $7.29
Previous CloseN/A
Volume346.43K
Average Volume (3M)2.16M
Market Cap
$90.81M
Enterprise Value$92.30M
Total Cash (Recent Filing)$90.20M
Total Debt (Recent Filing)$12.36M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Mar 12, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding97,986,630
10 Day Avg. Volume3,848,351
30 Day Avg. Volume2,161,142
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)3.84
Price to Sales (P/S)1143.94
P/FCF Ratio-3.89
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue485.82
Enterprise Value/Gross Profit-2.70
Enterprise Value/Ebitda-1.21
Forecast
1Y Price Target
$1.00Price Target Upside7.53% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Accelerated Approval PotentialThe current clinical data package could support an accelerated approval pathway for efzofitimod, offering a faster route to market if regulators accept the evidence.
Patient-reported OutcomesPrior clinical data showed efzofitimod improved a validated patient-reported lung symptom score by an amount considered clinically meaningful, supporting evidence of functional benefit for patients.
Phase 2 Interim ResultsInterim results from the Phase 2 EFZO-CONNECT study showed encouraging signals in patients with scleroderma-related interstitial lung disease, bolstering the case for advancing development.
Bears Say
Placebo Response ConfoundingStrong improvement in placebo patients during steroid tapering could make it harder to demonstrate a treatment benefit in future trials, complicating trial design and outcome interpretation.
Primary Endpoint MissThe EFZO-FIT study failing to meet its primary endpoint clouds the regulatory and commercial outlook, increasing the likelihood that additional trials will be required.
Regulatory UncertaintyAnalyst recommends holding the stock pending regulatory clarity from an FDA Type C meeting, reflecting uncertainty about an approvable development path for efzofitimod.
aTyr Pharma News
ATYR FAQ
What was aTyr Pharma’s price range in the past 12 months?
aTyr Pharma lowest stock price was $0.64 and its highest was $7.29 in the past 12 months.
What is aTyr Pharma’s market cap?
aTyr Pharma’s market cap is $90.81M.
When is aTyr Pharma’s upcoming earnings report date?
aTyr Pharma’s upcoming earnings report date is Mar 12, 2026 which is in 26 days.
How were aTyr Pharma’s earnings last quarter?
aTyr Pharma released its earnings results on Nov 06, 2025. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.184 by -$0.076.
Is aTyr Pharma overvalued?
According to Wall Street analysts aTyr Pharma’s price is currently Undervalued.
Does aTyr Pharma pay dividends?
aTyr Pharma does not currently pay dividends.
What is aTyr Pharma’s EPS estimate?
aTyr Pharma’s EPS estimate is -0.18.
How many shares outstanding does aTyr Pharma have?
aTyr Pharma has 97,986,630 shares outstanding.
What happened to aTyr Pharma’s price movement after its last earnings report?
aTyr Pharma reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.184. Following the earnings report the stock price went up 5.974%.
Which hedge fund is a major shareholder of aTyr Pharma?
Currently, no hedge funds are holding shares in ATYR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
aTyr Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.00 (7.53% Upside)
$1.00 (7.53% Upside)
Blogger Sentiment
Bullish
ATYR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.94%
12-Months-Change
Fundamentals
Return on Equity
-103.22%
Trailing 12-Months
Asset Growth
16.41%
Trailing 12-Months
Company Description
aTyr Pharma
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
ATYR Stock 12 Month Forecast
Average Price Target
$1.00
▲(7.53% Upside)
Technical Analysis
XBiotech
―
―
Prelude Therapeutics
―
Context Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
Ownership Overview
2.45% Insiders
26.47% Mutual Funds
1.17% Other Institutional Investors
61.97% Public Companies and Individual Investors
Options Prices
Currently, No data available
---